Close Menu

Palmetto

The final LCD covers AlloSure in renal allograft recipients who have a probability of active renal allograft rejection.

The genomic test is designed to help doctors decide which patients are at low enough risk that they can be more conservatively managed.

The molecular testing firm estimated that more than 70 percent of Medicare patients with prostate cancer will now have coverage for Prolaris.

The coverage decision limits the test to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue-based testing.

The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.

Genelex is hoping that a recently published randomized-controlled trial will help it get on better footing with Medicare.

Several MDx firms recently touted BCBS's Evidence Street opinions on their tests as milestones, and Palmetto GBA's MolDx may soon be using its assessments.

The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.

Palmetto GBA revised a final LCD for comprehensive genomic profiling in lung cancer, and issued similar draft determinations in other cancers.

The panel's decisions could change the codes diagnostic companies use to bill payors for these tests, which could affect revenue.

Pages